MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Viking Therapeutics Operating Income 2011-2026 | VKTX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Viking Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -393 M | -151 M | -101 M | -70.4 M | -55.7 M | -42.7 M | -32.7 M | -26.2 M | -19.1 M | -13.8 M | -12 M | -23.5 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -12 M | -393 M | -78.4 M |
Quarterly Operating Income Viking Therapeutics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -74.6 M | -55.5 M | - | -36.6 M | -34.1 M | -34.1 M | - | -27.3 M | -23.7 M | -20.5 M | - | -16.2 M | -17.6 M | -16.2 M | - | -13.4 M | -15.5 M | -14.2 M | - | -9.84 M | -10.6 M | -10.9 M | - | -7.44 M | -9.57 M | -6.81 M | - | -7.39 M | -6.92 M | -4.8 M | - | -4.69 M | -4.98 M | -4.97 M | - | -3.26 M | -3.58 M | -3.27 M | - | -4.29 M | -2.63 M | -461 K | - | -1.15 M | -21.8 M | -210 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -210 K | -74.6 M | -15.1 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.66 | - | $ 16.7 M |  USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 91.28 | - | $ 27.2 B | Germany |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Burford Capital Limited
BUR
|
242 M | $ 4.48 | - | $ 736 M |  Britain |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | France |
 |
Cerus Corporation
CERS
|
-8.68 M | $ 1.85 | - | $ 353 M | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Coherus BioSciences
CHRS
|
-181 M | $ 1.67 | - | $ 196 M | USA |
 |
Celldex Therapeutics
CLDX
|
-287 M | $ 31.37 | - | $ 2.08 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-17.3 M | $ 0.44 | - | $ 5.04 M |  Israel |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-16 M | $ 2.32 | - | $ 1.03 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
258 M | $ 24.98 | - | $ 3.05 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-85.3 M | $ 10.14 | - | $ 135 M | USA |
 |
Cardiff Oncology
CRDF
|
-49 M | $ 1.58 | - | $ 106 M | USA |
 |
Curis
CRIS
|
-5.71 M | $ 0.53 | - | $ 6.98 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-517 M | $ 37.7 | - | $ 3.55 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-665 M | $ 49.15 | - | $ 4.42 B |  Schweiz |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-24 M | - | -10.17 % | $ 12.2 K | USA |
 |
CytomX Therapeutics
CTMX
|
-22.4 M | $ 4.4 | - | $ 607 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
-42 M | $ 0.86 | - | $ 5.79 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Cue Biopharma
CUE
|
-26.6 M | $ 0.18 | - | $ 17.1 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
DBV Technologies S.A.
DBVT
|
-147 M | $ 20.36 | - | $ 2.84 B | France |
 |
AIkido Pharma
AIKI
|
-55.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Denali Therapeutics
DNLI
|
-487 M | $ 19.38 | - | $ 3.19 B | USA |
 |
Dyadic International
DYAI
|
-7.19 M | $ 0.87 | -2.8 % | $ 31.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
-17.3 M | $ 3.54 | - | $ 238 B | Britain |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Entera Bio Ltd.
ENTX
|
-11.1 M | $ 1.19 | - | $ 55.5 M | Israel |
 |
Equillium
EQ
|
-23.6 M | $ 2.01 | - | $ 115 M | USA |
 |
Allakos
ALLK
|
-196 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
502 M | $ 330.34 | - | $ 43.3 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
Fate Therapeutics
FATE
|
-148 M | $ 1.19 | - | $ 141 M | USA |
 |
Aileron Therapeutics
ALRN
|
-50.6 M | - | 10.36 % | $ 9.8 M | USA |